Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
June 23, 2021 08:30 ET
|
Entera Bio Ltd.
Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 monthsSubjects receiving the 2.5 mg dose of EB613 for...
Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union
June 17, 2021 08:00 ET
|
Entera Bio Ltd.
‒ Oral delivery technology has potential to transform $20 billion injectable biologics market ‒ ‒ Final BMD results from company’s Phase 2 Osteoporosis study of EB 613 expected in Q2/2021 ‒ ...
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
May 20, 2021 08:00 ET
|
Entera Bio Ltd.
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒ ‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including...
Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors
April 20, 2021 08:45 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron...
Entera Appoints Ramesh Ratan as Chief Financial Officer
April 15, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the...
New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress
April 06, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will...
Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020
March 18, 2021 08:00 ET
|
Entera Bio Ltd.
‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒‒ Final Data, Including Bone Mineral Density, Expected in Q2:21 ‒‒ FDA Approval of EB613 IND for the Treatment of Osteoporosis Enables...
Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021
March 11, 2021 16:15 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report...
Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
March 11, 2021 08:30 ET
|
Entera Bio Ltd.
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21 ‒ ...
Entera Bio To Present At The H.C. Wainwright Global Life Sciences Conference
March 04, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 04, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its...